96 related articles for article (PubMed ID: 31128003)
1. Surgery in initially metastatic breast cancer: prognosis is associated with patient characteristics and timing of surgery.
Xue F; Yu L; Lin Y; Wang Z; Li S; Shao N; Ye F; Gu C; Li X
J BUON; 2019; 24(2):543-548. PubMed ID: 31128003
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
4. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
Jimeno A; Amador ML; González-Cortijo L; Tornamira MV; Ropero S; Valentín V; Hornedo J; Cortés-Funes H; Colomer R
Cancer; 2004 May; 100(9):1833-42. PubMed ID: 15112263
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
[TBL] [Abstract][Full Text] [Related]
6. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
[TBL] [Abstract][Full Text] [Related]
8. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors and analyses of different therapeutic strategies in HR+ breast cancer patients with bone-only metastases].
Ding XY; Fan Y; Ma F; Li Q; Wang JY; Yuan P; Zhang P; Xu BH
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3279-82. PubMed ID: 23328514
[TBL] [Abstract][Full Text] [Related]
10. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
[TBL] [Abstract][Full Text] [Related]
13. A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Ozawa H; Sata A; Fukui R; Bun A; Higuchi T; Fujimoto Y; Miyagawa Y; Imamura M; Miyoshi Y
Anticancer Res; 2019 Oct; 39(10):5653-5662. PubMed ID: 31570463
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of primary site surgery on metastatic breast cancer patients at diagnosis.
Desille-Gbaguidi H; Avigdor S; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2019 Mar; 48(3):171-177. PubMed ID: 30352310
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
18. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
Breast Cancer; 2017 Nov; 24(6):748-755. PubMed ID: 28425014
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]